文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

原发肿瘤切除术治疗同时性不可切除转移的无症状结直肠癌患者：随机对照试验和病例匹配研究的荟萃分析。

Primary tumor resection for asymptomatic colorectal cancer patients with synchronous unresectable metastases: a meta-analysis of randomized controlled trials and case-matched studies.

机构信息

Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, China.

West China Medical School, Sichuan University, Chengdu, 610041, China.

出版信息

Langenbecks Arch Surg. 2024 Aug 6;409(1):242. doi: 10.1007/s00423-024-03414-9.

DOI:10.1007/s00423-024-03414-9
PMID:39105876
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11303460/
Abstract

PURPOSE: The value of upfront primary tumor resection (PTR) for asymptomatic unresectable metastatic colorectal cancer (mCRC) patients remains contentious. This meta-analysis aimed to assess the prognostic significance of upfront PTR for asymptomatic unresectable mCRC. METHODS: A systematic literature search was performed on June 21st, 2024. To minimize the bias and ensure robust evidence, only randomized controlled trials (RCTs) and case-matched studies (CMS) that compared PTR followed by chemotherapy to chemotherapy alone were included. The primary outcome was overall survival (OS), while cancer-specific survival (CSS) served as the secondary outcome. RESULTS: Eight studies (three RCTs and five CMS) involving 1221 patients were included. Compared to chemotherapy alone, upfront PTR followed by chemotherapy did not improve OS (hazard ratios [HR] 0.91, 95% confidence interval [CI] 0.79-1.04, P = 0.17), but was associated with slightly better CSS (HR 0.59, 95% CI 0.40-0.88, P = 0.009). CONCLUSIONS: The current limited evidence indicates that upfront PTR does not improve OS but may enhance CSS in asymptomatic unresectable mCRC patients. Ongoing trials are expected to provide more reliable evidence on this issue.

摘要

目的：对于无症状不可切除转移性结直肠癌（mCRC）患者，初始原发肿瘤切除（PTR）的价值仍存在争议。本荟萃分析旨在评估初始 PTR 对无症状不可切除 mCRC 患者的预后意义。

方法：于 2024 年 6 月 21 日进行系统文献检索。为了最大程度地减少偏倚并确保可靠的证据，仅纳入了比较 PTR 后化疗与单纯化疗的随机对照试验（RCT）和病例匹配研究（CMS）。主要结局为总生存期（OS），次要结局为癌症特异性生存期（CSS）。

结果：纳入了 8 项研究（3 项 RCT 和 5 项 CMS），共计 1221 例患者。与单纯化疗相比，PTR 后化疗并未改善 OS（风险比 [HR] 0.91，95%置信区间 [CI] 0.79-1.04，P=0.17），但 CSS 略有改善（HR 0.59，95% CI 0.40-0.88，P=0.009）。

结论：目前有限的证据表明，初始 PTR 并未改善 OS，但可能会提高无症状不可切除 mCRC 患者的 CSS。预期正在进行的试验将为这一问题提供更可靠的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/8bc108c3191e/423_2024_3414_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/af1324cea37b/423_2024_3414_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/23c7298e8407/423_2024_3414_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/2120f541961c/423_2024_3414_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/8bc108c3191e/423_2024_3414_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/af1324cea37b/423_2024_3414_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/23c7298e8407/423_2024_3414_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/2120f541961c/423_2024_3414_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db44/11303460/8bc108c3191e/423_2024_3414_Fig4_HTML.jpg

相似文献

[1]
Primary tumor resection for asymptomatic colorectal cancer patients with synchronous unresectable metastases: a meta-analysis of randomized controlled trials and case-matched studies.

Langenbecks Arch Surg. 2024-8-6

[2]
Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.

Ann Oncol. 2024-9

[3]
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.

Eur J Cancer. 2018-1-30

[4]
Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.

Int J Colorectal Dis. 2024-10-25

[5]
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.

J Surg Oncol. 2014-3-26

[6]
The impact of primary tumor resection for asymptomatic colorectal cancer patients with unresectable metastases: a systematic review and meta-analysis.

Int J Colorectal Dis. 2023-8-15

[7]
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.

J Clin Oncol. 2021-4-1

[8]
The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial.

Cancers (Basel). 2020-8-16

[9]
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.

Eur J Cancer. 2023-9

[10]
Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer.

Cochrane Database Syst Rev. 2012-8-15

引用本文的文献

[1]
Outcomes of upfront primary tumor resection in patients with synchronous wild-type metastatic colorectal cancer.

Am J Cancer Res. 2024-12-15

本文引用的文献

[1]
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.

J Clin Oncol. 2024-5-1

[2]
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.

Cancers (Basel). 2023-11-16

[3]
Clinical Outcomes of Upfront Primary Tumor Resection in Synchronous Unresectable Metastatic Colorectal Cancer.

Cancers (Basel). 2023-10-19

[4]
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.

Eur J Cancer. 2023-9

[5]
Effect of primary tumor resection on survival in patients with asymptomatic unresectable metastatic colorectal cancer: a systematic review and meta-analysis.

Expert Rev Anticancer Ther. 2023-1

[6]
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Ann Oncol. 2023-1

[7]
Primary tumor resection in patients with unresectable colorectal cancer with synchronous metastases could improve the activity of poly-chemotherapy: A trial-level meta-analysis.

Surg Oncol. 2022-9

[8]
Asymptomatic Primary Tumor Resection in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Front Oncol. 2022-3-29

[9]
Impact of Upfront Chemotherapy on the Effect of Primary Tumour Resection for Asymptomatic Synchronous Colorectal Cancer With Unresectable Metastases: A Propensity-Score-Matched Cohort Analysis.

Clin Med Insights Oncol. 2022-3-25

[10]
Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases.

Front Oncol. 2022-1-31

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索